Treatment issues with chronic hepatitis C: Special populations and pharmacy strategies

American Journal of Managed Care

Volumn 11, Issue SUPPL. 10, 2005, Pages

  Bacon, Bruce R ^a   McHutchison, John G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEMOPOIETIC GROWTH FACTOR; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

AFRICAN AMERICAN; ALOPECIA; AMNESIA; ARTICLE; BODY WEIGHT DISORDER; CHILL; CHRONIC HEPATITIS; CLINICAL PHARMACY; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DEPRESSION; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG COST; DRUG DOSE REDUCTION; DRY EYE; DYSPNEA; ECONOMIC ASPECT; FATIGUE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEALTH CARE COST; HEALTH CARE PLANNING; HEART PALPITATION; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHYROIDISM; HYPOTHYROIDISM; INSOMNIA; MAJOR CLINICAL STUDY; MANAGED CARE; MOOD DISORDER; MYALGIA; NAUSEA; NYSTAGMUS; PATIENT COMPLIANCE; PATIENT EDUCATION; PHOTOPHOBIA; PHOTOSENSITIVITY DISORDER; POPULATION RISK; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; VISUAL IMPAIRMENT; WEIGHT REDUCTION;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEPATITIS C, CHRONIC; HUMANS; MANAGED CARE PROGRAMS;

EID: 27644514603     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. McHutchison JG, Dev AT. Future trends in managing hepatitis C. Gastroenterol Clin North Am. 2004;33(suppl): S51-S61.
2. Gish RC. Treating hepatitis C: the state of the art. Gastroenterol Clin North Am. 2004;33(suppl):S1-S9.
3. National Institutes of Health. National Institutes of Health consensus development conference statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology. 2002;36(suppl 1):S3-S20.
4. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47 (RR-19):1-39.
5. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology. 2002;36(suppl 1):S114-S120.
6. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171.
7. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
8. Daniel S. Chronic hepatitis C treatment patterns in African American patients: an update. Am J Gastroenterol. 2005;100:716-722.
9. Nguyen MH, Whittemore AS, Garcia RT, et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol. 2004;2:820-824.
10. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology. 2003;37:1343-1350.
11. McHutchison JC, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Croup. Gastroenterology. 2000;119:1317-1323.
12. Kinzie JL, Naylor PH, Nathani MG, et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat. 2001;8:264-269.
13. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology. 1999;30:787-793.
14. Sterling RK, Hofmann CM, Luketic VA, et al. Treatment of chronic hepatitis C virus in the Virginia department of corrections: can compliance overcome racial differences to response? Am J Gastroenterol. 2004;99:866-872.
15. Muir AJ, Bornstein JD, Killenberg PG; Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265-2271.
16. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702-1708.
17. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med. 2004;117:163-168.
18. Jacobson I, Brown R, McCone J, et al. Weight-based ribavirin dosing improves virologic response in HCV-infected genotype-1 African-Americans (AA) compared to flat dose ribavirin with peginterferon alfa-2b combination therapy. Abstract presented at: 55th American Association for the Study of Liver Diseases annual meeting; October 29-November 2, 2004; Boston, Mass. Abstract 125.
19. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831-837.
20. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA. 2002;288:199-206.
21. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;33:240-247.
22. Greub C, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during anti-retroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800-1805.
23. De Luca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med. 2002;162:2125-2132.
24. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis. 2004;39:1507-1513.
25. Thomas DL. HIV/HCV coinfection; comorbidity and clinical implications. Adv Stud Med. 2005;5:S352-S355.
26. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562-569.
27. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054-1058.
28. Mehta SH, Thomas DL, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology. 2005;41:123-131.
29. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839-2848.
30. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
31. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.
32. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:F27-F36.
33. McHutchison JC, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-1492.
34. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004;40:484-490.
35. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426-1432.
36. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
37. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
38. Davis CL. Monitoring of viral levels during therapy of hepatitis C. Hepatology. 2002;36(suppl 1):S145-S151.
39. Wong JB, Davis CL, McHutchison JC, et al. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol. 2003;98:2354-2362.
40. McHutchison JC, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-1069.
41. Davis CL, Wong JB, McHutchison JC, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645-652.
42. Raptopoulou M, Tsantoulas D, Vafiadi I, et al. The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients. J Viral Hepat. 2005;12:91-95.
43. Manns MP. Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterol Clin North Am. 2004;33(suppl):S11-S24.
44. Mulhall BP, Younossi Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol. 2005;39(suppl):S23-S27.
45. Afdhal NH. Role of epoetin alfa in maintaining ribavirin dose. Gastroenterol Clin North Am. 2004;33(suppl): S25-S35.
46. Whitworth JE, Vanderpoel DR, Miller B. A descriptive assessment of the current treatment patterns for hepatitis C in a health benefits company population. Abstract presented at: Digestive Disease Week; May 14-19, 2005; Chicago, Ill. Abstract S1579.
47. Rowan PJ, Tabasi S, Abdul-Utif M, Kunik ME, El-Serag HB. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol. 2004;38:530-534.
48. Butt AA, Wagener M, Shakil AO, Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat. 2005;12:81-85.
49. Raison CL, Broadwell SD, Borisov AS, et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun. 2005;19:23-27.
50. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443-451.
51. National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health. Chronic hepatitis C: current disease management. Available at: www.digestive.niddk.nih.gov/ddisease/pubs/chronichepc/index.htm. Accessed September 12, 2005.
52. Shiffman ML. Retreatment of patients who do not respond to initial therapy for chronic hepatitis C. Cleve Clin J Med. 2004;71(suppl 3):S13-S16.